Affimed NV
NASDAQ:AFMD
Affimed NV
Cash from Operating Activities
Affimed NV
Cash from Operating Activities Peer Comparison
Competitive Cash from Operating Activities Analysis
Latest Figures & CAGR of Competitors
Company | Cash from Operating Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Affimed NV
NASDAQ:AFMD
|
Cash from Operating Activities
-€110.3m
|
CAGR 3-Years
-78%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-35%
|
|
BioNTech SE
NASDAQ:BNTX
|
Cash from Operating Activities
€5.4B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
MorphoSys AG
XETRA:MOR
|
Cash from Operating Activities
-€298.2m
|
CAGR 3-Years
-11%
|
CAGR 5-Years
-58%
|
CAGR 10-Years
N/A
|
|
CureVac NV
NASDAQ:CVAC
|
Cash from Operating Activities
-€267.9m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-29%
|
CAGR 10-Years
N/A
|
|
Immatics NV
NASDAQ:IMTX
|
Cash from Operating Activities
€18.2m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-3%
|
CAGR 10-Years
N/A
|
|
Biotest AG
XETRA:BIO
|
Cash from Operating Activities
-€2.7m
|
CAGR 3-Years
50%
|
CAGR 5-Years
36%
|
CAGR 10-Years
-8%
|
See Also
What is Affimed NV's Cash from Operating Activities?
Cash from Operating Activities
-110.3m
EUR
Based on the financial report for Dec 31, 2023, Affimed NV's Cash from Operating Activities amounts to -110.3m EUR.
What is Affimed NV's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 10Y
-35%
Over the last year, the Cash from Operating Activities growth was -5%. The average annual Cash from Operating Activities growth rates for Affimed NV have been -78% over the past three years , and -35% over the past ten years .